Skip to main content

Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance.

Publication ,  Journal Article
Clark, AS; West, KA; Blumberg, PM; Dennis, PA
Published in: Cancer Res
February 15, 2003

Drugs that target protein kinase C (PKC) are now being evaluated in patients with non-small cell lung cancer (NSCLC), but the role of PKC in NSCLC cells remains unclear. We report here that NSCLC cell lines show enhanced phosphorylation and altered expression of specific PKC isoforms compared with normal lung epithelial cells. PKC inhibition variably increased apoptosis, with rottlerin, a PKCdelta inhibitor, being most effective and potentiating chemotherapy-induced apoptosis, especially with trastuzumab. Consistent with PKCdelta being anti-apoptotic in NSCLC cells, transient transfection of a kinase-dead mutant of PKCdelta increased apoptosis and potentiated chemotherapy-induced apoptosis. Our studies provide a rationale for targeting PKC isoforms in NSCLC cells, especially PKCdelta.

Duke Scholars

Published In

Cancer Res

ISSN

0008-5472

Publication Date

February 15, 2003

Volume

63

Issue

4

Start / End Page

780 / 786

Location

United States

Related Subject Headings

  • Trastuzumab
  • Transfection
  • Protein Kinase C-delta
  • Protein Kinase C
  • Phosphorylation
  • Oncology & Carcinogenesis
  • Lung Neoplasms
  • Isoenzymes
  • Humans
  • Enzyme Inhibitors
 

Citation

APA
Chicago
ICMJE
MLA
NLM

Published In

Cancer Res

ISSN

0008-5472

Publication Date

February 15, 2003

Volume

63

Issue

4

Start / End Page

780 / 786

Location

United States

Related Subject Headings

  • Trastuzumab
  • Transfection
  • Protein Kinase C-delta
  • Protein Kinase C
  • Phosphorylation
  • Oncology & Carcinogenesis
  • Lung Neoplasms
  • Isoenzymes
  • Humans
  • Enzyme Inhibitors